Andreas R. Klatt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andreas R. Klatt has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Holzem
Department of Medicine III, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
8 shared publications - Alexandra da Palma Guerreiro
Department I of Internal Medicine, Center for Integrated Oncology Aachen, Faculty of Medicine and Cologne University Hospital, University of Cologne, Cologne, Germany
8 shared publications - Anna Brunn
Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
8 shared publications - Anthony Letai
Dana-Farber Cancer Institute, Boston, USA
8 shared publications - Ari M. Melnick
Josep Carreras Leukaemia Research Institute, Barcelona, Spain
8 shared publications - Arina Riabinska
Department of Neurosurgery, Experimental Neurosurgery/BCRT, Charite-Universitätsmedizin Berlin, Campus Mitte, Chariteplatz 1/Virchowweg 21, Aschheim-Zondek-Haus 03-003, 10117, Berlin, Germany
8 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 50 (5) , 255-264
CLEC3A: overview of an extracellular matrix lectin linking cartilage biology, tumor progression, and host defense
C-type lectin domain family 3 member A (CLEC3A) is an extracellular matrix (ECM)-associated protein involved in cartilage biology, cell signaling, and innate host defense. Over more than two decades of research at the Institute for Clinical Chemistry, University of Cologne, we have shown that CLEC3A, originally identified in cartilage, is a multifunctional regulator of tissue homeostasis and disease processes. Structurally, it belongs to the tetranectin subgroup of C-type lectins and contains domains that enable ECM association and multimer formation. Beyond its structural role in cartilage, CLEC3A modulates tissue-type plasminogen activator-mediated plasmin generation and contributes to extracellular matrix remodeling and cell-matrix interactions affecting adhesion and signaling. Altered CLEC3A expression has been reported in degenerative diseases such as osteoarthritis and intervertebral disc degeneration, as well as in cancer, where it is linked to PI3K–AKT signaling, tumor progression, and immune regulation, including programmed cell death-ligand 1 (PD-L1) regulation. CLEC3A serves as a precursor for bioactive antimicrobial peptides generated by proteolytic cleavage, which show activity against a broad range of bacterial and fungal pathogens, including multidrug-resistant organisms and Candida auris , mainly via membrane-disruptive mechanisms. Full-length CLEC3A also exhibits intrinsic antimicrobial activity. In vivo studies in biomaterial-associated infection models show reduced bacterial burden and inflammation, and peptide modifications can enhance potency, stability, and cytocompatibility. These findings highlight CLEC3A as a promising candidate for translational research in degenerative disease, oncology, and infection, although the underlying receptor-mediated mechanisms remain to be fully elucidated.
- 5 August 2026
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 50 (5) , 255-264
Open AccessCLEC3A: overview of an extracellular matrix lectin linking cartilage biology, tumor progression, and host defense
C-type lectin domain family 3 member A (CLEC3A) is an extracellular matrix (ECM)-associated protein involved in cartilage biology, cell signaling, and innate host defense. Over more than two decades of research at the Institute for Clinical Chemistry, University of Cologne, we have shown that CLEC3A, originally identified in cartilage, is a multifunctional regulator of tissue homeostasis and disease processes. Structurally, it belongs to the tetranectin subgroup of C-type lectins and contains domains that enable ECM association and multimer formation. Beyond its structural role in cartilage, CLEC3A modulates tissue-type plasminogen activator-mediated plasmin generation and contributes to extracellular matrix remodeling and cell-matrix interactions affecting adhesion and signaling. Altered CLEC3A expression has been reported in degenerative diseases such as osteoarthritis and intervertebral disc degeneration, as well as in cancer, where it is linked to PI3K–AKT signaling, tumor progression, and immune regulation, including programmed cell death-ligand 1 (PD-L1) regulation. CLEC3A serves as a precursor for bioactive antimicrobial peptides generated by proteolytic cleavage, which show activity against a broad range of bacterial and fungal pathogens, including multidrug-resistant organisms and Candida auris , mainly via membrane-disruptive mechanisms. Full-length CLEC3A also exhibits intrinsic antimicrobial activity. In vivo studies in biomaterial-associated infection models show reduced bacterial burden and inflammation, and peptide modifications can enhance potency, stability, and cytocompatibility. These findings highlight CLEC3A as a promising candidate for translational research in degenerative disease, oncology, and infection, although the underlying receptor-mediated mechanisms remain to be fully elucidated.
- Open Access
- 12 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (2) , 234
CLEC3A-Derived Antimicrobial Peptides Reduce Staphylococcus aureus Bacterial Counts in an In Vivo Biomaterial-Associated Infection Mouse Model
Background/Objectives: Biomaterials are an essential part of healthcare for both diagnostic and therapeutic procedures. Although some biomaterials possess antimicrobial properties, introducing biomaterial into the body may lead to infections due to bacterial adhesion on their surfaces and still poses a major clinical problem. Peptides derived from the human cartilage-specific C-type lectin domain family 3 member A (CLEC3A) show a potent antimicrobial effect. In addition, coating titanium, a commonly used prosthetic material, with the CLEC3A-derived AMPs HT-47 and WRK-30 greatly reduces the number of adherent bacteria in vitro. The aim of this study was to evaluate the effectiveness of CLEC3A-derived peptides HT-47 and WRK-30 in reducing bacterial adhesion and mitigating infection in vivo in a murine biomaterial-associated infection model. Methods: To do so, an in vivo mouse infection model was used, where titanium plates—either uncoated or coated with chimeric CLEC3A-derived peptides TiBP-HT-47 and TiBP-WRK-30—were implanted subcutaneously into mice. This was followed by the introduction of Staphylococcus aureus bacterial cultures to induce a biomaterial-associated infection. After 24 h, the titanium plates, surrounding tissue, and mice blood samples were investigated. Results: CLEC3A-coated titanium plates lead to a significantly lower bacterial count than uncoated ones. Additionally, they prevent the infection from spreading to the surrounding tissue. Moreover, mice with CLEC3A-coated implants display lower IL-6 serum levels and therefore decreased systemic inflammation. Conclusions: In conclusion, in this biomaterial-associated infection mouse-model, CLEC3A-derived peptides show in vivo antimicrobial activity by reducing bacterial burden on biomaterial and wound tissue and decreasing systemic inflammation, making them promising candidates for clinical applications.
- 12 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (2) , 234
Open AccessCLEC3A-Derived Antimicrobial Peptides Reduce Staphylococcus aureus Bacterial Counts in an In Vivo Biomaterial-Associated Infection Mouse Model
Background/Objectives: Biomaterials are an essential part of healthcare for both diagnostic and therapeutic procedures. Although some biomaterials possess antimicrobial properties, introducing biomaterial into the body may lead to infections due to bacterial adhesion on their surfaces and still poses a major clinical problem. Peptides derived from the human cartilage-specific C-type lectin domain family 3 member A (CLEC3A) show a potent antimicrobial effect. In addition, coating titanium, a commonly used prosthetic material, with the CLEC3A-derived AMPs HT-47 and WRK-30 greatly reduces the number of adherent bacteria in vitro. The aim of this study was to evaluate the effectiveness of CLEC3A-derived peptides HT-47 and WRK-30 in reducing bacterial adhesion and mitigating infection in vivo in a murine biomaterial-associated infection model. Methods: To do so, an in vivo mouse infection model was used, where titanium plates—either uncoated or coated with chimeric CLEC3A-derived peptides TiBP-HT-47 and TiBP-WRK-30—were implanted subcutaneously into mice. This was followed by the introduction of Staphylococcus aureus bacterial cultures to induce a biomaterial-associated infection. After 24 h, the titanium plates, surrounding tissue, and mice blood samples were investigated. Results: CLEC3A-coated titanium plates lead to a significantly lower bacterial count than uncoated ones. Additionally, they prevent the infection from spreading to the surrounding tissue. Moreover, mice with CLEC3A-coated implants display lower IL-6 serum levels and therefore decreased systemic inflammation. Conclusions: In conclusion, in this biomaterial-associated infection mouse-model, CLEC3A-derived peptides show in vivo antimicrobial activity by reducing bacterial burden on biomaterial and wound tissue and decreasing systemic inflammation, making them promising candidates for clinical applications.
- Open Access
- 25 December 2023
- Published by MDPI AG in Applied Sciences
- Vol. 14 (1) , 184
Antimicrobial Activity of Human C-Type Lectin Domain Family 3 Member A (CLEC3A)
C-type lectins (CTLs) are a group of proteins that play a crucial role in immunological functions. With the rise of antibiotic-resistant bacteria, CTLs have emerged as a potential alternative to traditional antibiotics and antimicrobial peptides (AMPs), the latter exhibiting limited application due to their low biostability. In this study, we used viable count assays to investigate the antimicrobial activity of the human C-type Lectin Domain Family 3 Member A (CLEC3A) and its two protein domains, CLEC3A Ex23 and CLEC3A Ex3, against gram-positive and gram-negative bacteria. Additionally, using immunoblot analysis, we assessed the biostability of CLEC3A and its protein domains in bacterial supernatant and murine serum. Our findings demonstrate that CLEC3A, CLEC3A Ex23, and CLEC3A Ex3 possess antimicrobial activity against gram-positive Staphyloccocus aureus and gram-negative Pseudomonas aeruginosa. CLEC3A is more effective against P. aeruginosa than the well-investigated antimicrobial peptide LL-37. Furthermore, CLEC3A and its domains have low sensitivity to bacterial and serum proteases, making them more advantageous for systemic application than most AMPs. In conclusion, our research has demonstrated that CLEC3A is not only a precursor of AMPs but also an antimicrobial protein itself, with favorable characteristics for therapeutic applications.
- 25 December 2023
- Published by MDPI AG in Applied Sciences
- Vol. 14 (1) , 184
Open AccessAntimicrobial Activity of Human C-Type Lectin Domain Family 3 Member A (CLEC3A)
C-type lectins (CTLs) are a group of proteins that play a crucial role in immunological functions. With the rise of antibiotic-resistant bacteria, CTLs have emerged as a potential alternative to traditional antibiotics and antimicrobial peptides (AMPs), the latter exhibiting limited application due to their low biostability. In this study, we used viable count assays to investigate the antimicrobial activity of the human C-type Lectin Domain Family 3 Member A (CLEC3A) and its two protein domains, CLEC3A Ex23 and CLEC3A Ex3, against gram-positive and gram-negative bacteria. Additionally, using immunoblot analysis, we assessed the biostability of CLEC3A and its protein domains in bacterial supernatant and murine serum. Our findings demonstrate that CLEC3A, CLEC3A Ex23, and CLEC3A Ex3 possess antimicrobial activity against gram-positive Staphyloccocus aureus and gram-negative Pseudomonas aeruginosa. CLEC3A is more effective against P. aeruginosa than the well-investigated antimicrobial peptide LL-37. Furthermore, CLEC3A and its domains have low sensitivity to bacterial and serum proteases, making them more advantageous for systemic application than most AMPs. In conclusion, our research has demonstrated that CLEC3A is not only a precursor of AMPs but also an antimicrobial protein itself, with favorable characteristics for therapeutic applications.
- Open Access
- 11 October 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (10) , 1532
Modified CLEC3A-Derived Antimicrobial Peptides Lead to Enhanced Antimicrobial Activity against Drug-Resistant Bacteria
Antimicrobial peptides (AMPs) represent a promising alternative to conventional antibiotics. Sequence changes can significantly improve the therapeutic properties of antimicrobial peptides. In our study, we apply different sequence modifications to enhance the performance of the CLEC3A-derived AMPs HT-16 and HT-47. We truncated their sequences, inserting a triple-glycine linker, adding an N-terminal tryptophan residue, and generating a D-amino acid variant, resulting in the generation of seven new peptides. We investigated their antimicrobial activity against gram-positive and gram-negative bacteria, their cytotoxicity to murine cells, and the biostability of the modified peptides in serum. We identified a novel antimicrobial peptide, WRK-30, with enhanced antimicrobial potency against S. aureus and MRSA. Additionally, WRK-30 was less cytotoxic to eukaryotic cells, allowing its application in higher concentrations in an in vivo setting. In conclusion, we identified a novel CLEC3A-derived antimicrobial peptide WRK-30 with significantly improved therapeutic properties and the potential to widen the repertoire of conventional antibiotics.
- 11 October 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (10) , 1532
Open AccessModified CLEC3A-Derived Antimicrobial Peptides Lead to Enhanced Antimicrobial Activity against Drug-Resistant Bacteria
Antimicrobial peptides (AMPs) represent a promising alternative to conventional antibiotics. Sequence changes can significantly improve the therapeutic properties of antimicrobial peptides. In our study, we apply different sequence modifications to enhance the performance of the CLEC3A-derived AMPs HT-16 and HT-47. We truncated their sequences, inserting a triple-glycine linker, adding an N-terminal tryptophan residue, and generating a D-amino acid variant, resulting in the generation of seven new peptides. We investigated their antimicrobial activity against gram-positive and gram-negative bacteria, their cytotoxicity to murine cells, and the biostability of the modified peptides in serum. We identified a novel antimicrobial peptide, WRK-30, with enhanced antimicrobial potency against S. aureus and MRSA. Additionally, WRK-30 was less cytotoxic to eukaryotic cells, allowing its application in higher concentrations in an in vivo setting. In conclusion, we identified a novel CLEC3A-derived antimicrobial peptide WRK-30 with significantly improved therapeutic properties and the potential to widen the repertoire of conventional antibiotics.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
Pharmacological Screen IC50 values
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
Pharmacological Screen IC50 values